Search research articles
Contact Us
Filters
Showing results (581-590 of 800) with videos related to
Page
of 80
Sort By:
Pituitary
|
December 17, 2009
The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome
Anne Klibanski, Shlomo Melmed, David R Clemmons, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland
|
June 22, 2021
Antitumour necrosis factor therapy is associated with de novo Crohn's disease after ileal pouch-anal anastomosis
Adam Truong, Karen N Zaghiyan, James Mirocha, et al.
Journal of Clinical Medicine
|
September 5, 2020
Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
Konstantinos Papamichael, Valerio J Thomas, Andrea Banty, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 5, 2007
Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study
Gil Y Melmed, Robert Elashoff, Gary C Chen, et al.
Inflammatory Bowel Diseases
|
June 1, 2018
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Kevin L Winthrop, Gil Y Melmed, Séverine Vermeire, et al.
Transfusion
|
October 22, 2011
The difference between fingerstick and venous hemoglobin and hematocrit varies by sex and iron stores
Ritchard G Cable, Whitney R Steele, Russell S Melmed, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 10, 2020
Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael, William T Clarke, Niels Vande Casteele, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 15, 2025
Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment
Remo Panaccione, Gil Y Melmed, David Drobne, et al.
Advances in Therapy
|
August 10, 2024
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons
Walter Reinisch, Gil Y Melmed, Hiroshi Nakase, et al.
Nature Reviews. Endocrinology
|
July 28, 2018
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed, Marcello D Bronstein, Philippe Chanson, et al.
Page
of 80
Search research articles
Search
Showing results (581-590 of 800) with videos related to
Sort By:
Page
of 80
Pituitary
|
December 17, 2009
The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome
Anne Klibanski, Shlomo Melmed, David R Clemmons, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland
|
June 22, 2021
Antitumour necrosis factor therapy is associated with de novo Crohn's disease after ileal pouch-anal anastomosis
Adam Truong, Karen N Zaghiyan, James Mirocha, et al.
Journal of Clinical Medicine
|
September 5, 2020
Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
Konstantinos Papamichael, Valerio J Thomas, Andrea Banty, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 5, 2007
Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study
Gil Y Melmed, Robert Elashoff, Gary C Chen, et al.
Inflammatory Bowel Diseases
|
June 1, 2018
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Kevin L Winthrop, Gil Y Melmed, Séverine Vermeire, et al.
Transfusion
|
October 22, 2011
The difference between fingerstick and venous hemoglobin and hematocrit varies by sex and iron stores
Ritchard G Cable, Whitney R Steele, Russell S Melmed, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 10, 2020
Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael, William T Clarke, Niels Vande Casteele, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 15, 2025
Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment
Remo Panaccione, Gil Y Melmed, David Drobne, et al.
Advances in Therapy
|
August 10, 2024
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons
Walter Reinisch, Gil Y Melmed, Hiroshi Nakase, et al.
Nature Reviews. Endocrinology
|
July 28, 2018
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed, Marcello D Bronstein, Philippe Chanson, et al.
Page
of 80